Price and cost-effectiveness analysis of the Indian version of ibrutinib

The Indian version of ibrutinib (Ibrutinib) is a generic version of the drug that has been widely used in the global market in recent years, especially in India and other developing countries. Compared with the original drug, the price of the Indian version of ibrutinib is significantly lower, making this treatment option affordable to more patients. Usually, the price of the Indian version of ibrutinib is about 1,000 yuan, which is much lower than the price of the domestic original drug.

In China, the original drug of ibrutinib is already on the market and included in medical insurance, but the price is relatively high. Generally speaking, the price of ibrutinib in the domestic market is about 8,000 yuan. The specific medical insurance reimbursement price can be consulted through the local hospital pharmacy. Although supported by medical insurance, the price is still relatively high for some patients, which may affect their purchasing power and continuity of treatment.

Compared with the domestic original drug, the price of the Indian version of ibrutinib is undoubtedly more advantageous. Indian generic drugs are not only more affordable, but also have almost the same ingredients as the original drugs, ensuring consistency in efficacy. The specifications of the Indian version of ibrutinib are usually 140 mg to 120 tablets or 140 mg to 112 tablets, etc., and the price is generally around 1,000 yuan. For patients, choosing the Indian version of ibrutinib can significantly reduce treatment costs, especially for those who need to take the drug for a long time.

However, the price of the Bangladeshi Becan version of ibrutinib is relatively high, about 4,000 yuan, which is still cheaper than the domestic original drug. However, compared with the Indian version, the Bangladeshi version does not show the same price advantage. Therefore, if patients wish to purchase cheaper generic versions of ibrutinib, the Indian version is clearly a more cost-effective option. When purchasing, patients should make reasonable choices based on factors such as personal circumstances, drug availability, and medical insurance policies.

Reference materials:https://www.imbruvica.com/